Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination With Filgrastim in Early Recovery Post-Myocardial Infarction

NCT03486080 is registered in ClinicalTrials.gov with Recardio, Inc. as lead sponsor.

NCT NCT03486080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03486080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination With Filgrastim in Early Recovery Post-Myocardial Infarction
Lead sponsor
Recardio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 7, 2018
Completion date
February 26, 2021
Enrollment
49 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction, acute myocardial ischemia, stemi - st elevation myocardial infarction